Cargando…

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam

We investigated the effects of cannabidiol (CBD; 21‐day maintenance dose) on the pharmacokinetics (PK) of clobazam (CLB) and monitored the safety of CBD (or placebo) plus CLB in 20 patients with uncontrolled epilepsy on stable doses of CLB. Blood samples collected until 24 hours postdose were evalua...

Descripción completa

Detalles Bibliográficos
Autores principales:	VanLandingham, Kevan E., Crockett, Julie, Taylor, Lesley, Morrison, Gilmour
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	NON COVID ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540496/ https://www.ncbi.nlm.nih.gov/pubmed/32652616 http://dx.doi.org/10.1002/jcph.1634

Ejemplares similares

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
por: Morrison, Gilmour, et al.
Publicado: (2019)

Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs
por: Patsalos, Philip N., et al.
Publicado: (2020)

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy
por: Ben-Menachem, Elinor, et al.
Publicado: (2020)

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
por: Devinsky, Orrin, et al.
Publicado: (2020)

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
por: Taylor, Lesley, et al.
Publicado: (2019)

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
por: Gunning, Boudewijn, et al.
Publicado: (2020)

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
por: Taylor, Lesley, et al.
Publicado: (2018)

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
por: Anderson, Lyndsey L., et al.
Publicado: (2019)

Effect of clobazam as add-on antiepileptic drug in patients with epilepsy
por: Joshi, Rupa, et al.
Publicado: (2014)

Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users
por: Schippers, Frank, et al.
Publicado: (2020)

Clobazam: The phoenix drug (from the very old to the brand new)
por: Guerreiro, Carlos A. M.
Publicado: (2014)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects
por: Crockett, Julie, et al.
Publicado: (2020)

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
por: Privitera, Michael, et al.
Publicado: (2021)

Clobazam and Its Use in Epilepsy
por: Pernea, Marius, et al.
Publicado: (2016)

Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome
por: François, Clément, et al.
Publicado: (2017)

The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia
por: Ralvenius, William T., et al.
Publicado: (2016)

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
por: Tayo, Bola, et al.
Publicado: (2019)

Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
por: Brennan, Christina M, et al.
Publicado: (2022)

Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis
por: Purohit, Vivek, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule‐1 (MAdCAM‐1), in Patients With Ulcerative Colitis or Crohn's Disease
por: Wang, Yi, et al.
Publicado: (2020)

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
por: Posada, Maria M., et al.
Publicado: (2020)

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects
por: Tellone, Valeria, et al.
Publicado: (2020)

Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection
por: Deng, Rong, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study
por: Vanhoutte, Frédéric, et al.
Publicado: (2020)

Exploring the Relationship Between Morphine Concentration and Oversedation in Children After Cardiac Surgery
por: Valkenburg, Abraham J., et al.
Publicado: (2020)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation
por: Renaud, Lionel, et al.
Publicado: (2020)

Formulation and optimization of fast dissolving intraoral drug delivery system for clobazam using response surface methodology
por: Bala, Rajni, et al.
Publicado: (2013)

Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: a randomized, double-blind, placebo-controlled trial.
por: Pessoa, R. M. D. P. P., et al.
Publicado: (2023)

Hypothermia associated with clobazam use in adult epilepsy
por: Gauthier, Angela C., et al.
Publicado: (2016)

Effects of clobazam for treatment of refractory status epilepticus
por: Madžar, Dominik, et al.
Publicado: (2016)

A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam
por: Tolbert, Dwain, et al.
Publicado: (2018)

Review of Instrumented Indentation
por: VanLandingham, Mark R.
Publicado: (2003)

The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment
por: Lawn, Will, et al.
Publicado: (2023)

Systematic review of clobazam use in patients with status epilepticus
por: Mahmoud, Sherif Hanafy, et al.
Publicado: (2018)

Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate
por: Hau Man, To Harmony, et al.
Publicado: (2017)

Drug-Drug Interactions Between Cannabidiol and Lithium
por: Singh, Rani K., et al.
Publicado: (2020)

The efficacy and safety of cannabidiol as adjunct treatment for drug‐resistant idiopathic epilepsy in 51 dogs: A double‐blinded crossover study
por: Rozental, Aaron J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iha9hlmc9b4336dkegjnqvqsfr